Cerebrospinal fluid levels of alpha-synuclein, amyloid β, tau, phosphorylated tau, and neuron-specific enolase in patients with Parkinson’s disease, dementia with Lewy bodies or other neurological disorders: Their relationships with cognition and nuclear medicine imaging findings

• Published in: Neuroscience letters Vol. 715; p. 134564
• Main Authors: Katayama, Takayuki, Sawada, Jun, Kikuchi-Takeguchi, Shiori, Kano, Kohei, Takahashi, Kae, Saito, Tsukasa, Okizaki, Atsutaka, Hasebe, Naoyuki
• Format: Journal Article
• Language: English
• Published: Ireland Elsevier B.V 10.01.2020
• Subjects: Aged; Aged, 80 and over; Alpha-synuclein; alpha-Synuclein - cerebrospinal fluid; Amyloid beta-Peptides - cerebrospinal fluid; Amyloid β; Biomarkers - cerebrospinal fluid; Cognitive Dysfunction - cerebrospinal fluid; Cognitive Dysfunction - diagnostic imaging; Dementia with Lewy bodies; Female; Humans; Lewy Body Disease - cerebrospinal fluid; Lewy Body Disease - diagnostic imaging; Male; Middle Aged; Nervous System Diseases - cerebrospinal fluid; Nervous System Diseases - diagnostic imaging; Neuron specific enolase; Nuclear Medicine - methods; Parkinson Disease - cerebrospinal fluid; Parkinson Disease - diagnostic imaging; Parkinson’s disease; Peptide Fragments - cerebrospinal fluid; Phosphopyruvate Hydratase - cerebrospinal fluid; Phosphorylation - physiology; Tau; tau Proteins - cerebrospinal fluid; Tau; Neuron specific enolase; Amyloid β; Alpha-synuclein; Parkinson’s disease; Dementia with Lewy bodies
• ISSN: 0304-3940; 1872-7972; 1872-7972
• DOI: 10.1016/j.neulet.2019.134564

•Cerebrospinal fluid α-synuclein level is decreased in Parkinson’s disease.•Tau and neuron specific enolase are elevated in non-Parkinson disorders.•Elevated amyloid β42 level is an independent predictor of cognitive decline.•Decrease on dopamine transporter imaging is not correlated with α-synuclein level. Parkinson’s disease (PD) and dementia with Lewy bodies (DLB) are common neurodegenerative disorders, but no established biochemical markers for these diseases have been identified. We enrolled 78 subjects (27 patients with PD/DLB, 34 patients with non-PD/DLB neurodegenerative disorders [non-PD/DLB], and 17 controls). Cerebrospinal fluid (CSF) was collected via the standard lumbar puncture technique. The CSF levels of alpha-synuclein, amyloid β40, amyloid β42, tau, phosphorylated tau (p-tau), neuron-specific enolase (NSE), and hemoglobin were measured with enzyme-linked immunosorbent assays. Dopamine transporter imaging with 123I-ioflupane was also performed. The PD/DLB patients exhibited significantly lower CSF alpha-synuclein levels than non-PD/DLB group. Significantly elevated CSF levels of tau, p-tau, and NSE were detected in the non-PD/DLB group. Multivariate analysis revealed that the mini-mental state examination score was correlated with the CSF amyloid β42 level. The specific binding ratio on 123I-ioflupane imaging was decreased in the PD/DLB group, but it was not correlated with the CSF alpha-synuclein level. These results indicate that (1) the CSF alpha-synuclein level is a useful biomarker of PD/DLB; (2) the CSF levels of tau, p-tau, and NSE can be used to discriminate PD/DLB from non-PD/DLB; and (3) the CSF amyloid β42 level is an independent predictor of cognitive decline in neurological disorders.